Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 16/20 | 0.54 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23575650 | 0.93 | CSF1R (0.57) | CSF1RPTPN11SYK | |
| SCHEMBL23575854 | 0.88 | MAPT (0.59) | SLC2A1 | |
| SCHEMBL23629074 | 0.87 | CSF1R (0.62) | CSF1RSLC2A1LRRK2CYP3A4CYP2C9 | |
| SCHEMBL23575656 | 0.81 | MAPT (0.60) | SLC2A1 | |
| SCHEMBL23575743 | 0.81 | CSF1R (0.62) | CSF1RLRRK2CYP3A4CYP2C9 | |
| SCHEMBL29220526 | 0.81 | POLB (0.51) | CSF1RPTPN11SYK | |
| SCHEMBL23575817 | 0.79 | PDE4B (0.49) | CSF1R | |
| SCHEMBL29220515 | 0.78 | POLB (0.49) | CSF1RPTPN11SYK | |
| SCHEMBL23575616 | 0.76 | CSF1R (0.49) | CSF1RLRRK2 | |
| SCHEMBL23629089 | 0.75 | JAK2 (0.51) | PTPN11SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3846800-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | C4 Therapeutics, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20210198256-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | C4 THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-20210198256-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | C4 THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198256-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | RBBP9, MTHFD1, BRWD1 | CSF1R 3115/4885PTPN11 3794/4885SLC2A1 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.